University of Lodz   Report issue

Academic/Hospital Phase 2 Phase 4
Founded: Łódź Poland (1945)

Organization Overview

First Clinical Trial
2003
NCT01555736
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Alternative names

Department of Immunopathology Chair of Allergy, Immunology and Dermatology Faculty of Biomedical Sciences and Postgraduate Training Medical University of Lodz | Department of Internal Diseases, Asthma and allergy, Medical University of Lodz | University of Lodz, Lodz, Poland

Active Ingredients

Drugs in Phase 4 Trials (2)

rye pollens (1 trial)

timothy grass pollen allergen extract (Grastek) (1 trial)

Drugs in Phase 2 Trials (3)

azd-1981 (1 trial)

docetaxel (taxotere) (1 trial)

efungumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Breast Neoplasms (Phase 2)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 5